US 11,946,939 B2
Biomarkers and methods for assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients
Kerri Ford, South San Francisco, CA (US); and Jeffrey R. Curtis, Birmingham, AL (US)
Assigned to Laboratory Corporation of America Holdings, Burlington, NC (US)
Filed by LABORATORY CORPORATION OF AMERICA HOLDINGS, Burlington, NC (US); and UAB RESEARCH FOUNDATION, Birmingham, AL (US)
Filed on Mar. 15, 2021, as Appl. No. 17/201,985.
Application 17/201,985 is a continuation of application No. 16/814,530, filed on Mar. 10, 2020, granted, now 10,962,552.
Application 16/814,530 is a continuation of application No. PCT/US2018/050817, filed on Sep. 13, 2018.
Claims priority of provisional application 62/558,436, filed on Sep. 14, 2017.
Prior Publication US 2021/0199671 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); G16H 10/40 (2018.01); G16H 50/20 (2018.01)
CPC G01N 33/6893 (2013.01) [G16H 10/40 (2018.01); G16H 50/20 (2018.01); G01N 2333/4737 (2013.01); G01N 2333/575 (2013.01); G01N 2800/52 (2013.01); G01N 2800/54 (2013.01); G01N 2800/60 (2013.01)] 18 Claims
 
1. A method for treating cardiovascular disease (CVD) or infection in a subject with rheumatoid arthritis (RA), the method comprising:
performing an immunoassay on a sample from the subject to generate a dataset comprising protein level data for at least four protein markers of the group comprising chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta-urogastrone) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); and, vascular endothelial growth factor A (VEGFA), wherein the at least four protein markers comprise LEP, CRP, CHI3L1, and MMP1; and
calculating a risk score for the sample indicating CVD or infection present in the subject by combining the dataset with a clinical parameter and a clinical assessment; and
administering a therapeutic regimen to the subject comprising one or more of:
administering a therapeutic compound selected from a Disease-modifying antirheumatic drug (DMARD), a biologic DMARD, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid;
administering dietary modification and/or supplementation; and
administering bariatric surgical intervention.